507 results on '"van den Berkmortel, Franchette"'
Search Results
2. lnsights into Adjuvant Systemic Treatment Selection for Patients with Stage III Melanoma: Data from the Dutch Cancer Registry
3. Deep learning on CT scans to predict checkpoint inhibitor treatment outcomes in advanced melanoma
4. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma
5. Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic model
6. Baseline tumor-infiltrating lymphocyte patterns and response to immune checkpoint inhibition in metastatic cutaneous melanoma
7. Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma
8. Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021
9. High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial
10. Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial.
11. Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study
12. Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy
13. Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
14. Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies
15. CT radiomics compared to a clinical model for predicting checkpoint inhibitor treatment outcomes in patients with advanced melanoma
16. Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting
17. Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry
18. Adjuvant treatment for melanoma in clinical practice – Trial versus reality
19. Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study
20. Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry
21. Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy
22. ASO Visual Abstract: Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
23. Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors
24. Adjuvant treatment with anti‐PD‐1 in acral melanoma: A nationwide study.
25. Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study
26. Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands – A nationwide population-based study
27. Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting
28. End-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma: A Nationwide Cohort Study
29. Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients
30. Lower risk of severe checkpoint inhibitor toxicity in more advanced disease
31. First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis
32. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma
33. Baseline tumor-infiltrating lymphocyte patterns and response to immune checkpoint inhibition in metastatic cutaneous melanoma
34. Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma
35. Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study
36. Long-Term Survival in Patients With Advanced Melanoma
37. Adjuvant treatment with anti-PD-1 in acral melanoma:A nationwide study
38. Long-Term Survival in Patients With Advanced Melanoma
39. BRAF/MEK inhibitor rechallenge in advanced melanoma patients
40. A prediction model for response to immune checkpoint inhibition in advanced melanoma
41. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma
42. A prediction model for response to immune checkpoint inhibition in advanced melanoma
43. BRAF/MEK inhibitor rechallenge in advanced melanoma patients
44. Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021
45. Improving survival in advanced melanoma patients:a trend analysis from 2013 to 2021
46. The impact of colorectal surgery on health-related quality of life in older functionally dependent patients with cancer – A longitudinal follow-up study
47. BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma
48. A prediction model for response to immune checkpoint inhibition in advanced melanoma
49. BRAF/MEK inhibitor rechallenge in advanced melanoma patients
50. Patient- and tumor-related predictors of chemotherapy intolerance in older patients with cancer: A systematic review
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.